Sweden's Xspray Q4 pretax loss narrows

Xspray Pharma publ AB

12/02/2026 07:09

Overview

Sweden pharmaceutical firm's Q4 net sales amounted to SEK 0, with significant pretax loss

Company received FDA CRL for Dasynoc due to contract manufacturer deficiencies

Company prepares for US market launch of two drugs in 2026

Outlook

Xspray expects FDA re-inspection of contract manufacturer's plant in first half of 2026

Company anticipates potential US launch of two CML drugs in second half of 2026

Xspray plans to finance operations through autumn 2026, may seek additional capital

Result Drivers

REGULATORY CHALLENGES - FDA issued a CRL for Dasynoc due to contract manufacturer deficiencies, impacting approval process

MARKET PREPARATIONS - Co is preparing for potential US launch of two drugs in 2026, aiming to transition to a commercial pharmaceutical company

KEY OPINION LEADER SUPPORT - Positive response from clinics and opinion leaders confirms need for co's technology

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 0
Q4 Adjusted EPS
-SEK 0.89
Q4 Adjusted Free Cash Flow
-SEK 41.37 mln
Q4 Pretax Profit
-SEK 37.009 mln


Analyst Coverage

Wall Street's median 12-month price target for XSpray Pharma AB (publ) is SEK60.00, about 148.4% above its February 11 closing price of SEK24.15

The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nMFN1wRYf5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)